Nemocnice Pardubickeho kraje a.s.

The cardiovascular disease program at Nemocnice Pardubickeho kraje a.s. evaluates new therapies for heart attacks, chronic heart failure, hypertension and lipid disorders, aiming to reduce major adverse events and improve long‑term outcomes.

• Acute myocardial infarction management and early intervention
• Heart failure with preserved or mildly reduced ejection fraction
• LDL‑cholesterol lowering and anti‑inflammatory approaches
• Prevention of venous thromboembolism after pulmonary embolism
• Risk reduction in patients with high cardiovascular risk

With 37 active trials and 31 investigators, the department leverages its hospital setting in Pardubice to advance cardiovascular care across Europe.

Research in bacterial infections and mycoses focuses on vaccine safety, immune response profiling, and preventative strategies for vulnerable populations, including children and immunocompromised adults.

• Evaluation of a pentavalent meningococcal vaccine in infants, toddlers and children
• Assessment of immune response durability after vaccination
• Safety monitoring of novel antimicrobial prophylaxis in high‑risk patients
• Exploration of immunogenicity markers for bacterial disease prevention

The site’s expertise in infectious disease supports the development of safer, more effective prevention tools for bacterial and fungal threats.

The department’s digestive system disease portfolio investigates innovative treatments for inflammatory bowel conditions, targeting disease remission and quality of life improvements.

• Maintenance therapy for moderate to severe Crohn’s disease
• Long‑term safety of oral agents for ulcerative colitis
• Therapeutic drug monitoring to optimize dosing
• Endoscopic response as a measure of treatment success

By conducting 37 trials with a multidisciplinary team, the site contributes to advancing care for patients with chronic gastrointestinal disorders.

Studies on immune system diseases aim to enhance immune modulation, prevent infections in immunosuppressed patients, and evaluate novel biologics for auto‑immune conditions.

• Prevention of major infections in hypogammaglobulinemia receiving B‑cell depletion therapy
• Evaluation of IL‑6 inhibition to lower cardiovascular risk in post‑MI patients
• Safety of new monoclonal antibodies in myasthenia gravis subtypes
• Immune response to investigational vaccines in children

The hospital’s integrated immunology expertise supports the translation of cutting‑edge immunotherapies into clinical practice.

The musculoskeletal disease research program evaluates botulinum toxin formulations and other agents to reduce spasticity and improve motor function after neurological injury.

• Upper‑limb spasticity treatment following stroke or traumatic brain injury
• Lower‑limb spasticity management with botulinum toxin injections
• Dose‑finding studies for new spasticity therapies
• Long‑term safety of repeated spasticity interventions

Through collaboration among 31 investigators, the site advances therapeutic options for patients with post‑stroke and traumatic spasticity.

Clinical investigations into nervous system diseases explore disease‑modifying agents for multiple sclerosis, Parkinson’s disease, and peripheral neuropathies, seeking to slow progression and improve daily functioning.

• Subcutaneous versus intravenous formulation comparison in multiple sclerosis
• Spasticity reduction in MS using FAAH/MAGL inhibition
• OFF‑time reduction in Parkinson’s disease with novel oral agents
• Safety and efficacy of new treatments for chronic inflammatory demyelinating polyneuropathy

The department’s neurologic focus, combined with robust trial infrastructure, supports the development of next‑generation neurotherapeutics.

Research on otorhinolaryngologic diseases targets chronic rhinosinusitis, nasal polyps, and sudden sensorineural hearing loss, testing novel biologics and drug delivery methods to improve sinus health and auditory outcomes.

• Anti‑IL‑33 antibody for reduction of nasal polyp size
• Brensocatib efficacy in chronic rhinosinusitis without nasal polyps
• Single‑dose middle‑ear injection versus oral steroids for sudden hearing loss
• Long‑term safety of intranasal therapies in chronic sinus disease

By integrating ENT specialists with clinical research teams, the site advances therapeutic options for upper airway and auditory disorders.

The respiratory tract disease portfolio includes studies on acute pulmonary embolism and strategies to prevent thromboembolic complications, aiming to reduce mortality and hospital readmissions.

• Catheter‑directed thrombolysis versus standard anticoagulation in intermediate‑high risk pulmonary embolism
• Evaluation of novel anticoagulant agents for venous thromboembolism prevention
• Impact of early in‑hospital initiation of heart failure drugs on respiratory outcomes
• Safety monitoring of respiratory adverse events in cardiovascular trials

The hospital’s multidisciplinary approach enables comprehensive assessment of respiratory complications in cardiovascular and thrombotic conditions.